Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease

Technology appraisal guidance
Reference number: TA217
Published: 23 March 2011
Last updated: 20 June 2018

Appendix B - proposal paper presented to the Institute's Guidance Executive

Appendix B - proposal paper presented to the Institute's Guidance Executive

Appendix B - proposal paper presented to the Institute's Guidance Executive
23 April 2014
(873.38 Kb 14 sec)

Adobe Acrobat reader required.

Adobe Acrobat reader required.

This page was last updated: 16 December 2014